IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (1198)	8/11/1997 12:39:00 AM
From: Pseudo Biologist	of 1762

Rick, thanks for the insight. You probably know this but for completeness and to fill in the blanks for me and others: - IDEC licensed CD40L (=gp39) technology from Dartmouth (RJ Noelle, I am guessing) and is working with Esai, a Japanese company on this. Their humanized anti-gp39 Ab may enter the clinic any time; not clear if they have been able to produce a good primatized version at this point. - Biogen licensed 5c8, a mouse Mab against CD40L from Columbia (Seth Lederman et al). A patent has been issued to Columbia, and Biogen has rights to it. I have not checked the claims of this patent, but the link is patent.womplex.ibm.com for those interested. 5c8 is the same Mab used in the recent PNAS paper and according to Biogen's web page it has started human trials (not clear in which form: mouse, chimeric or humanized?) - How about the B7/CD28/CTLA4 part of the (recent PNAS) study; besides AHP/GI who else may be in business here? -And, please do tell us about the "other four major areas" Max

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next